Paper Details

  1. Home
  2. Paper Details

Targeting Casein Kinase 1 (CK1) in Hematological Cancers.

Author: BryjaVítězslav, JanovskáPavlína, MiskinHari, NormantEmmanuel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review summarizes recent developments in the understanding of biology and therapeutic potential of the inhibition of CK1 isoforms in the pathogenesis of hematological malignancies. CK1δ/ε inhibitors block CLL development in preclinical models via inhibition of WNT-5A/ROR1-driven non-canonical Wnt pathway.
Paper Details　
Original Abstract of the Article :
The casein kinase 1 enzymes (CK1) form a family of serine/threonine kinases with seven CK1 isoforms identified in humans. The most important substrates of CK1 kinases are proteins that act in the regulatory nodes essential for tumorigenesis of hematological malignancies. Among those, the most import...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730698/

データ提供：米国国立医学図書館（NLM）

Targeting Casein Kinase 1 (CK1) in Hematological Cancers: A Promising Avenue for Treatment

The field of hematological oncology is constantly evolving, seeking new and effective treatments for various blood cancers. This study investigates the potential of targeting casein kinase 1 (CK1) enzymes as a therapeutic strategy for a range of hematological malignancies. The authors reviewed recent research on the role of CK1 in the pathogenesis of different blood cancers, exploring the potential of inhibiting CK1 activity to combat these diseases. Like a seasoned explorer uncovering hidden pathways in a vast and complex landscape, the authors navigate the intricacies of CK1 biology and its potential as a therapeutic target.

CK1 Inhibition: A Potential Weapon Against Hematological Cancers

The study highlights the potential of CK1 inhibitors in treating hematological cancers, specifically showcasing their promising preclinical activity in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and multiple myeloma (MM).

A New Era in Cancer Treatment: Exploiting the Power of CK1 Inhibition

This research underscores the potential of CK1 inhibitors as novel therapeutic agents for a range of hematological malignancies. It demonstrates the importance of targeting specific molecular pathways to develop effective cancer treatments.

Dr.Camel's Conclusion

This study delves into the potential of targeting CK1 enzymes for the treatment of hematological cancers. It provides valuable insights into the complex molecular mechanisms involved in these diseases and highlights the promise of CK1 inhibitors as a potential avenue for future therapies.

Date :
  1. Date Completed 2021-03-04
  2. Date Revised 2021-03-04
Further Info :

Pubmed ID

33261128

DOI: Digital Object Identifier

PMC7730698

Related Literature

Article Analysis
・Effects of umbralisib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.